clinical trial · NCT05744063
A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients
Swedish Orphan Biovitrum·phase4·completed·n = 13
Primary Hemophagocytic LymphohistiocytosisEmapalumab-Lzsg 5 MG/ML [Gamifant]
brief summary
The goal of this post-authorization study is to describe safety and efficacy of emapalumab in treatment experienced Chinese patients with pHLH.
started
Feb 3, 2023
primary completion
Feb 21, 2025
completion
Aug 8, 2025
last updated
Mar 13, 2026
detailed description
This is an open-label, multi center, single arm, post-authorization study aiming to describe safety and efficacy of emapalumab in treatment experienced Chinese patients with confirmed or suspected primary hemophagocytic lymphohistiocytosis (pHLH). The main objectives of the study are to collect safety and efficacy data on emapalumab in treatment experienced Chinese pHLH patients
official title
An Open Label, Single Arm, Multi-Centre, Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of Primary Hemophagocytic Lymphohistiocytosis in Treatment Experienced Chinese Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol